Navicixizumab Combo Shows Benefit in Heavily Pretreated Ovarian Cancer
April 2, 2020 10:45 amBy Jason M. Broderick
The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study.
The data build on positive … Read more